Terray, a chemistry-first AI biotechnology company built at the intersection of AI and experimentation, is presenting at several conferences in October and November.

At these conferences, CEO Jacob Berlin will discuss the opportunities for applying AI to drug discovery; Terray’s unique ability to discover and develop novel small molecule medicines; and the progress the company has made in the past year toward the clinic and delivering life-changing medicines to patients.

Goldman Sachs Healthcare Private Company Conference

Terray is a chemistry-first AI biotechnology company built at the intersection of AI and experimentation. Terray’s EMMI (Experimentation Meets Machine Intelligence) platform combines proprietary hardware, scale data, chemistry-first AI and lab-in-the-loop automation to find and develop novel medicines for patients in need. Terray is developing transformative small-molecule medicines for an internal immunology pipeline and across multiple other therapeutic areas with partners, including BMS and Gilead. www.terraytx.ai

Terray to Present at Fall Investor Conferences